PIRFENIDONE
PULMONARY FIBROSIS TREATMENT AGENTS - ANTIFIBROTIC THERAPY · IDIOPATHIC PULMONARY FIBROSIS
SANDOZ
Drug class
Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy
The phrase "Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy" is a commercial formulary compendium category—specifically applied to pirfenidone—rather than a formal FDA-established pharmacologic class. Read more about Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy
34 drugs in this class 27 manufacturers
Drugs in Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy
PIRFENIDONE
PULMONARY FIBROSIS TREATMENT AGENTS - ANTIFIBROTIC THERAPY · IDIOPATHIC PULMONARY FIBROSIS
MICRO LABS USA,
ESBRIET (pirfenidone)
PULMONARY FIBROSIS TREATMENT AGENTS - ANTIFIBROTIC THERAPY · IDIOPATHIC PULMONARY FIBROSIS
LEGACY PHARMA I
PIRFENIDONE
PULMONARY FIBROSIS TREATMENT AGENTS - ANTIFIBROTIC THERAPY · IDIOPATHIC PULMONARY FIBROSIS
AUROBINDO PHARM
NINTEDANIB ESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE ·+2
DR.REDDY'S LAB
NINTEDANIB ESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE ·+2
APOTEX CORP
NINTEDANIB ESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE ·+2
CIPLA USA, INC.
NINTEDANIB ESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE ·+2
EDENBRIDGE/DEXC
NINTEDANIB ESYLATE
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS · SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE ·+2
SANDOZ
Filter & compare in the drug finder →
Opens the drug finder with Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy preselected. Add indication or manufacturer filters there.
The phrase "Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy" is a commercial formulary compendium category—specifically applied to pirfenidone—rather than a formal FDA-established pharmacologic class.
Clinically, these agents exert antifibrotic, anti-inflammatory, and antioxidant properties by downregulating pro-fibrotic growth factors and cytokines, notably transforming growth factor-beta (TGF-beta), thereby inhibiting fibroblast proliferation and collagen synthesis.
Their primary therapeutic role is to slow the decline of lung function and reduce disease progression in adults with idiopathic pulmonary fibrosis (IPF) and related progressive fibrosing interstitial lung diseases.
-
webmdrx.com
The phrase "Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy" is a commercial formulary compendium category—specifically applied to pirfenidone—rather than a formal FDA-established pharmacologic class
-
pihhealth.org
The phrase "Pulmonary Fibrosis Treatment Agents - Antifibrotic Therapy" is a commercial formulary compendium category—specifically applied to pirfenidone—rather than a formal FDA-established pharmacologic class
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.